Cappon Gregg D, Fleeman Tammye L, Rocca Meredith S, Cook Jon C, Hurtt Mark E
Pfizer Global Research and Development, Building 274 MS 1260, Eastern Point Road, Groton, CT 06340, USA.
Birth Defects Res B Dev Reprod Toxicol. 2003 Oct;68(5):421-7. doi: 10.1002/bdrb.10039.
Hoshi et al. [Hoshi et al. J Toxicol Sci 10(Suppl):187-255, 1985a,b,c,d] evaluated the potential for hydroxypropyl methylcellulose acetate succinate (HPMCAS) to produce developmental and reproductive toxicity in a series of studies that included rat and rabbit teratology studies, a rat fertility study, and a rat peri- and postnatal study. The authors concluded that there were no compound-related findings. In the cesarean-section phase of the rat teratology study, however, clubfoot was reported for 0.8, 2.1, 5.5, and 4.1% of fetuses in the control, 625, 1250, and 2500 mg/kg groups, respectively. There were no significant increases in external anomalies, but the apparent dose-related increase in clubfoot was not specifically addressed. In the rabbit teratology study, the number of litters evaluated (12-13 per group) was not consistent with current regulatory guidelines. Therefore, to definitively establish the potential of HPMCAS to produce developmental toxicity, embryo/fetal development studies were carried out in rats and rabbits.
Groups of 20 pregnant Sprague-Dawley rats and New Zealand White rabbits were dosed with 0, 50, 150, 625, or 2500 mg/kg HPMCAS from gestational day (GD) 6-17 or GD 7-19 for rats and rabbits, respectively. Fetuses were collected by cesarean section and examined for external, visceral and skeletal development.
No developmental toxicity was observed as a result of HPMCAS exposure demonstrating that maternal HPMCAS exposure during gestation does not induce developmental anomalies. There were no findings of clubfoot or other limb anomalies in these studies at dose levels equivalent to those that were previously associated with a possible increase in clubfoot.
The conclusion of the earlier study indicating that treatment with HPMCAS at doses up to and including 2500 mg/kg did not produce developmental toxicity was confirmed with these studies. It is likely that the clubfoot noted in the earlier rat teratology study was a misdiagnosis or artifact.
星野等人[星野等人,《毒理学杂志》10(增刊):187 - 255,1985年a、b、c、d期]在一系列研究中评估了羟丙基甲基纤维素乙酸琥珀酸酯(HPMCAS)产生发育毒性和生殖毒性的可能性,这些研究包括大鼠和家兔致畸学研究、大鼠生育力研究以及大鼠围产期和产后研究。作者得出结论,未发现与化合物相关的结果。然而,在大鼠致畸学研究的剖宫产阶段,对照组、625、1250和2500 mg/kg组中分别有0.8%、2.1%、5.5%和4.1%的胎儿出现了马蹄内翻足。外部畸形没有显著增加,但马蹄内翻足明显的剂量相关性增加未得到具体探讨。在家兔致畸学研究中,所评估的窝数(每组12 - 13窝)不符合当前的监管指南。因此,为明确确定HPMCAS产生发育毒性的可能性,在大鼠和家兔中进行了胚胎/胎儿发育研究。
分别于妊娠第6 - 17天(大鼠)和第7 - 19天(家兔),对20只怀孕的斯普拉格 - 道利大鼠和新西兰白兔分组给予0、50、150、625或2500 mg/kg的HPMCAS。通过剖宫产收集胎儿,并检查其外部、内脏和骨骼发育情况。
HPMCAS暴露未观察到发育毒性,表明孕期母体暴露于HPMCAS不会诱发发育异常。在这些研究中,在相当于先前与马蹄内翻足可能增加相关的剂量水平下,未发现马蹄内翻足或其他肢体异常。
这些研究证实了早期研究的结论表明,给予高达2500 mg/kg剂量的HPMCAS治疗不会产生发育毒性。早期大鼠致畸学研究中记录的马蹄内翻足很可能是误诊或人为现象。